- Home
- EMD vs CTMX Comparison
EMD vs CTMX Comparison
Compare EMD & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EMD
- CTMX
- Stock Information
- Founded
- EMD 2003
- CTMX 2008
- Country
- EMD United States
- CTMX United States
- Employees
- EMD N/A
- CTMX N/A
- Industry
- EMD Finance/Investors Services
- CTMX Biotechnology: Pharmaceutical Preparations
- Sector
- EMD Finance
- CTMX Health Care
- Exchange
- EMD Nasdaq
- CTMX Nasdaq
- Market Cap
- EMD 601.7M
- CTMX 544.2M
- IPO Year
- EMD N/A
- CTMX 2015
- Fundamental
- Price
- EMD $10.37
- CTMX $3.20
- Analyst Decision
- EMD
- CTMX Strong Buy
- Analyst Count
- EMD 0
- CTMX 5
- Target Price
- EMD N/A
- CTMX $5.30
- AVG Volume (30 Days)
- EMD 248.5K
- CTMX 4.5M
- Earning Date
- EMD 01-01-0001
- CTMX 11-06-2025
- Dividend Yield
- EMD 10.25%
- CTMX N/A
- EPS Growth
- EMD N/A
- CTMX 263.20
- EPS
- EMD N/A
- CTMX 0.49
- Revenue
- EMD N/A
- CTMX $141,100,000.00
- Revenue This Year
- EMD N/A
- CTMX N/A
- Revenue Next Year
- EMD N/A
- CTMX N/A
- P/E Ratio
- EMD N/A
- CTMX $6.54
- Revenue Growth
- EMD N/A
- CTMX 18.01
- 52 Week Low
- EMD $7.85
- CTMX $0.40
- 52 Week High
- EMD $9.55
- CTMX $3.51
- Technical
- Relative Strength Index (RSI)
- EMD 52.32
- CTMX 61.74
- Support Level
- EMD $10.12
- CTMX $3.21
- Resistance Level
- EMD $10.45
- CTMX $3.48
- Average True Range (ATR)
- EMD 0.14
- CTMX 0.20
- MACD
- EMD 0.00
- CTMX -0.03
- Stochastic Oscillator
- EMD 70.71
- CTMX 33.71
About EMD Western Asset Emerging Markets Debt Fund Inc
Western Asset Emg Markets Debt Fund Inc is a non-diversified closed-end management, and long term investment company. The primary investment objective of the company is to seek high current income and the secondary objective is to seek capital appreciation.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.